Ftse Mib
33.154,05
-0,10%
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
NASDAQ
17.732,60
-0,71%
Bitcoin
60.891,14
0,96%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSX Eupraxia Pharmaceuticals Inc (EPRX) Eupraxia Pharmaceuticals Inc (EPRX) Notizie

EPRX

Eupraxia Pharmaceuticals (EPRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:EPRX
DataOraFonteTitoloSimboloCompagnia
06/06/202423:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersTSX:EPRXEupraxia Pharmaceuticals Inc
05/06/202413:00PR Newswire (US)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024TSX:EPRXEupraxia Pharmaceuticals Inc
23/05/202423:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
22/05/202413:00PR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
21/05/202423:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
14/05/202413:00PR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
08/05/202423:03PR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
02/05/202413:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
11/04/202413:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
08/04/202413:00PR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
05/04/202413:00PR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
03/04/202423:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
01/04/202423:01PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
12/03/202414:41PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
12/03/202414:39PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
11/03/202421:06PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
11/03/202421:04PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/202423:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
01/02/202413:00PR Newswire (Canada)Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
30/01/202413:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeTSX:EPRXEupraxia Pharmaceuticals Inc
09/01/202400:44PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusTSX:EPRXEupraxia Pharmaceuticals Inc
12/12/202313:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE TrialTSX:EPRXEupraxia Pharmaceuticals Inc
11/12/202313:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Clinical and Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
14/11/202323:01PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
01/11/202312:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of RheumatologyTSX:EPRXEupraxia Pharmaceuticals Inc
11/10/202313:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
11/09/202321:32PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
07/09/202323:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Change of AuditorTSX:EPRXEupraxia Pharmaceuticals Inc
06/09/202323:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023TSX:EPRXEupraxia Pharmaceuticals Inc
19/08/202301:20PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125TSX:EPRXEupraxia Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:EPRX

La tua Cronologia

BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
SPM
Saipem
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
STMMI
ST Microelectronics
BIT
ENEL
Enel
BIT
TEN
Tenaris
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
CPR
Davide Campari
BIT
TRN
Terna Trasmissione Elett...
BIT
RACE
Ferrari NV
BIT
PRY
Prysmian
BIT
SRG
Snam
BIT
LDO
Leonardo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network